Replies to post #749796 on NorthWest Biotherapeutics Inc (NWBO)

[ilovetech]

Yep, it certainly looks to be playing out that way.

Here's how sales of Provenge have fared since it gained approval:

Annual revenue for Provenge has varied over the years, including $228 million in 2011, $303 million in 2016, and less than $500 million in 2021. Explanation
In 2011, Dendreon's gross revenue from Provenge sales was about $228 million. In 2016, Provenge's annual revenue was $303 million.e
In 2021, Provenge's brand was valued at less than $500 milion. The COVID-19 pandemic hurt sales of Provenge. In 2014, Dendreon's revenue increased by $20.1 million due to increased use of Provenge.
Provenge is a therapeutic vaccine used to treat prostate cancer. It's manufactured by Dendreon, a biotechnology company that develops and sells cancer therapeutics.
Some factors that have affected Provenge's sales include:
Cost: Provenge is expensive to produce and can cost tens of thousands of dollars per course.
Complexity: Provenge is complex to administer.
Reimbursement: Uncertainty about reimbursement status has deterred doctors from prescribing Provenge.